Abeona Therapeutics Inc. (NASDAQ:ABEO)
| Market Cap | 289.54M-8.3% |
| Revenue (ttm) | 25.52M+6280.0% |
| Net Income | -62.89M-209.9% |
| EPS | -1.11-281.2% |
| Shares Out | 57.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 31, 2000 |
| Volume | 736,722 |
| Open | 4.95 |
| Previous Close | 5.01 |
| Day's Range | 4.94 - 5.09 |
| 52-Week Range | 4.00 - 7.65 |
| Beta | 1.30 |
| Analysts | Buy |
| Price Target | 17.67(+247.83%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ABEO
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ABEO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABEO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABEO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABEO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ABEO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABEO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABEO
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.94M |
| IWMiShares Russell 2000 ETF | $6.02M |
| VXFVanguard Extended Market ETF | $3.67M |
| VTWOVanguard Russell 2000 ETF | $1.47M |
| SURISimplify Propel Opportunities ETF | $1.40M |
| IWCiShares Micro-Cap ETF | $722.97K |
Estimated from each fund’s disclosed top holdings × AUM
ABEO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABEO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score